The strong Phase 2 results significantly de-risk ML-007C-MA, likely driving upside in the stock. Key catalysts to watch: the FDA End-of-Phase 2 meeting outcome, initiation of the confirmatory pivotal trial, and topline data from the ongoing VISTA trial in Alzheimer's disease psychosis (expected 2H 2027). The cognitive signal could support a differentiated label, potentially expanding the addressable market beyond schizophrenia.
Price Chart
Executive Summary
MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia. The 210/3 mg BID dose met the primary endpoint (PANSS total score, p=0.015, ES=0.37) and showed a statistically significant cognitive improvement (ES=0.51, p=0.041) with a favorable safety profile. These data support advancement to a confirmatory pivotal trial and an End-of-Phase 2 meeting with the FDA.
Key Facts
- Phase 2 ZEPHYR trial met its primary endpoint: 210/3 mg BID dose showed statistically significant improvement in PANSS total score vs placebo at Week 5 (LS mean difference -4.5, p=0.015, effect size 0.37).
- Prespecified secondary endpoint: cognitive composite score improved significantly (effect size 0.51, p=0.041) in participants with baseline cognitive impairment, independent of antipsychotic effect.
- Key secondary endpoints also met: CGI-S (ES=0.48, p=0.002) and PANSS Positive Marder Factor (ES=0.39, p=0.012).
- Safety profile: no serious or drug-related severe adverse events, low GI-related discontinuation (2%), no metabolic, hepatic, or movement-related signals, no fasting requirement, one-dose titration.
- The 330/6 mg QD dose did not achieve statistical significance on the primary endpoint but showed numerical improvement.
- Company plans to engage with FDA at End-of-Phase 2 meeting and initiate a confirmatory pivotal trial to support NDA submission.
Financial Impact
Positive Phase 2 data de-risks ML-007C-MA, a potential multi-billion dollar schizophrenia therapy with a potentially differentiated cognitive benefit and tolerability profile. The filing compares effect sizes to approved antipsychotics with peak sales ranging from $2.0B to $6.2B, suggesting significant commercial potential if confirmed in Phase 3.
Risk Factors
- Phase 3 trials may fail to replicate the Phase 2 results.
- The 330/6 mg QD dose did not meet the primary endpoint, leaving uncertainty around a once-daily regimen.
- Regulatory pathway and FDA feedback at EOP2 meeting could introduce delays or additional requirements.
- Competition from existing muscarinic agonists (Cobenfy) and other pipeline agents may limit market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-316820 |
| Document: d139086d8k.htm | 0001193125-26-316820 |
| Document: d139086dex992.htm | 0001193125-26-316820 |
| Document: 0001193125-26-316820-index-headers.html | 0001193125-26-316820 |
| Document: 0001193125-26-316820-index.html | 0001193125-26-316820 |
| Document: 0001193125-26-316820.txt | 0001193125-26-316820 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Insider Cluster | $8.00 | awaiting T+20 | — | $7.91 (+1.19%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.91 (+2.66%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.91 (+2.66%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.91 (+2.66%) |
Sep 24, 2026 4w ago | EFFECT | $10.76 $8.25 | ▼ −23.33% | ▼ −22.91% | $7.91 (−26.53%) |
Sep 18, 2026 5w ago | S-1/A | $10.90 $8.00 | ▼ −26.61% | ▼ −25.70% | $7.91 (−27.48%) |
Aug 4, 2026 11w ago | Insider Cluster | $12.92 $13.06 | ▲ +1.08% | ▲ +1.69% | $7.91 (−38.82%) |
Aug 3, 2026 12w ago | 144 | $12.94 $13.31 | ▲ +2.86% | ▲ +4.10% | $7.91 (−38.91%) |
Jul 30, 2026 12w ago | 144 | $13.02 $12.60 | ▲ +3.23% | ▲ +6.21% | $7.91 (+39.29%) |
Jul 28, 2026 12w ago | Insider Buy | $15.02 $12.86 | ▼ −14.38% | ▼ −19.40% | $7.91 (−47.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers